Interestingly, our data presented here and previous work2 indicate that PD-1-mutation status could serve as a potential biomarker for genotype-specific vulnerabilities in T cell lymphomas. This evidence concerns the gene PDCD1 and T-cell non-Hodgkin lymphoma.